Search

Displaying results 4451 - 4460 of 10000 in total
  1. Drug

    Rhodamine 6G

    go.drugbank.com/drugs/DB03825
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Fosfructose

    go.drugbank.com/drugs/DB13863
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    HGTV-43

    go.drugbank.com/drugs/DB05807
    Experimental

    HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. … HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.

  4. Drug

    PDPSC18

    go.drugbank.com/drugs/DB05167
    Experimental

    PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.

  5. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    protein expression in cell culture. … ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  6. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

  7. Drug

    Quinestrol

    go.drugbank.com/drugs/DB04575
    Approved

    The 3-cyclopentyl ether of ethinyl estradiol.

  8. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro. … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  9. Drug

    Eprotirome

    go.drugbank.com/drugs/DB05035
    Investigational

    Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.

  10. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.